Basic Ordering Agreement 75N95018G00019
Award Date
9/7/18
Last Date to Order
9/6/23
Federal Agency
National Institute on Drug Abuse
Awardee
Sri International
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Employment Eligibility Verification
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
This indefinite delivery contract (IDC) was awarded by the National Institute on Drug Abuse (NIDA), a component of the U.S. Department of Health and Human Services, to Sri International, a non-profit research and development institute. The $9.75 million IDC has a period of performance from September 12, 2023 to September 11, 2028 and is for toxicological evaluations of potential medications to support NIDA's mission. Under this IDC, Sri International has been awarded two task orders so far....
This Indefinite Delivery Contract (IDC) is a single-award contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to Sri International, a non-profit research and development organization. The contract, valued at a ceiling of $342,897, is for the provision of IN VITRO METABOLISM AND NON-CLINICAL ADME STUDIES over a 5-year period of performance from September 27, 2021 to April 25, 2025. The contract was not set aside for any specific business size or socioeconomic...
The National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) awarded a $6.5 million single-award Indefinite Delivery Contract (IDC) to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization, to assess potential treatments for drug-induced respiratory depression and overdose toxicity. The contract has a period of performance from September 26, 2022 to September 25, 2027. Under this IDC, NIDA has issued several cost-plus-fixed-fee delivery...
The National Institute on Drug Abuse (NIDA), a civilian agency under the Department of Health and Human Services, has awarded an Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, to provide synthesis and distribution services for drugs of abuse and related compounds. The contract has a ceiling value of $14,004,330 and a period of performance from June 9, 2022 to June 8, 2027. This contract supports NIDA's mission of conducting...
The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH), has awarded an Indefinite Delivery Contract (IDC) to Actuated Medical, Inc., doing business as Piezo Resonance Innovations Inc. The $35 million, single-award IDC runs through September 2028 and is for research and development services related to biocompatibility testing, animal studies, and sterilization testing in support of NIDA's Blueprint MedTech (BPMT) Initiative. This work involves...
The National Institutes of Health National Institute on Drug Abuse (NIDA) awarded an indefinite delivery contract to the nonprofit Research Triangle Institute (RTI) International for the Preparation and Distribution of Research Drug Products. The contract, valued at up to $19,975,000, has a period of performance from September 20, 2019 to September 19, 2024 and does not utilize any set-aside designations. Under this contract, RTI provides a variety of services to NIDA including the...
The National Institute on Drug Abuse (NIDA), a civilian federal agency, awarded a single-award Indefinite Delivery Contract to Research Triangle Institute (RTI International), a non-profit research organization, for the preparation and distribution of research drug products. The $19,975,000 contract has a period of performance from March 20, 2025 to March 19, 2029, with a final completion date of March 19, 2026 for the initial $1,497,865 delivery order. RTI International, an experienced...
The National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS), has awarded an indefinite delivery/indefinite quantity (IDIQ) contract to The Emmes Company LLC, a for-profit limited liability company, to serve as the NIDA Data, Statistics, and Clinical Trial Support Center. Under this single-award IDIQ contract valued up to $31.2 million over a five-year period from September 2022 to September 2027, The...
The federal contract IDV award is for safety evaluation and toxicology studies and related services to support drug development efforts of the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH). The prime contractor, SRI International, a nonprofit research and development institute, will provide in vitro and in vivo exploratory and Investigational New Drug (IND)-directed toxicology studies for small molecule and biologic...
This indefinite delivery contract was awarded by the National Cancer Institute, a component of the U.S. Department of Health and Human Services, to the non-profit research and development institute SRI International. The single-award contract, valued at a ceiling of $12,069,385, is for the analysis and synthesis of GMP and non-GMP bulk drugs and pharmaceutical formulations. With a period of performance running through April 2028, this contract enables the National Cancer Institute to efficiently...